$REGN New Survey Reveals the Widespread of Moderate-to-Severe Atopic Dermatitis


New Survey Reveals the Widespread and Serious Impact of Moderate-to-Severe Atopic Dermatitis on People Living with the Disease

“We hear first-hand from people living with this disease that many aspects of their everyday life are impacted,” said Julie Block, President and CEO, National Eczema Association. “They routinely deal with intense itch and pain, and feeling self-conscious because of the way their skin looks. People share that they feel depressed and anxious because of their disease.”

Out of the 505 Americans with moderate-to-severe atopic dermatitis who responded to the Understand AD survey:

  • 53 percent reported that their disease has negatively impacted their daily lives
  • 82 percent have made lifestyle modifications, such as avoiding social engagements, being in pictures and participating in sports/exercise
  • 55 percent reported that their confidence was negatively impacted due to their disease
  • 49 percent say their sleep has been negatively impacted by the disease, moderately or significantly
  • 23 percent of people feel depressed and 28 percent feel anxious due to their AD
  • 20 percent report that their AD has impacted their ability to maintain employment and 16 percent have made career choices that limit face-to-face interactions with others because of the disease

The survey also found that nearly 70 percent of respondents often or sometimes experience flares while on treatment. In fact, people reported using a range of treatments to manage their disease including prescription therapies, over-the-counter medications, alternative medicine like acupuncture, and even vitamins and herbal supplements.

“Despite currently available treatment options, people living with moderate-to-severe atopic dermatitis still struggle to manage their disease,” said Susan Tofte, MS, BSN, FNP-C, past President of the Dermatology Nurses’ Association. “These survey results reaffirm what our community of nurses sees regularly with the people they are treating for this disease – the total impact goes beyond the physical symptoms. It’s important for all of us to do our part in recognizing this is more than just a skin disease.”

Visit www.UnderstandAD.com for additional survey findings, hear from people living with the disease, and to get connected with advocates such as the National Eczema Association and Dermatology Nurses’ Association. Award-winning chef, media personality and restaurateur Elizabeth Falkner, who has lived with atopic dermatitis for the past 20 years, also shares her personal experience on the website.

About Moderate-to-Severe Atopic Dermatitis
Moderate-to-severe atopic dermatitis, a serious, chronic form of eczema,i is characterized by rashes and can include intense itching, skin dryness, cracking, redness, crusting, and oozing.ii Even though atopic dermatitis symptoms appear on the skin, they are fueled by a continuous cycle of underlying inflammation triggered in part by a malfunction in the immune system.iii People living with the physical symptoms of atopic dermatitis may also feel self-conscious and embarrassed about their appearance and may experience anxiety, depression, and feelings of social isolation.iv,v,vi,vii,viii,ix,x

About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (SAN.PA) and in New York (SNY).

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

Genzyme® is a registered trademark of Genzyme Corporation. Sanofi® is a registered trademark of Sanofi. All rights reserved.

About Regeneron Pharmaceuticals, Inc.
Regeneron (REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. For additional information about the company, please visit www.regeneron.com  or follow @Regeneron on Twitter.


Please enter your comment!
Please enter your name here